A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Mutation
  • Receptor, Epidermal Growth Factor

abstract

  • These results provide the first example of successful therapeutic intervention with targeted therapy to overcome crizotinib resistance in a ROS1-rearranged cancer. Clin Cancer Res; 22(10); 2351-8. ©2015 AACR.

publication date

  • May 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4867287

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-15-2013

PubMed ID

  • 26673800

Additional Document Info

start page

  • 2351

end page

  • 8

volume

  • 22

number

  • 10